eMedicine Specialties > Infectious Diseases > Lower Respiratory Tract Infections
Legionnaires Disease
Updated: Feb 5, 2008
Introduction
Background
Legionella pneumophila is an important cause of both nosocomial and community-acquired pneumonia (CAP) and must be considered a possible causative pathogen in any patient who presents with pneumonia.
The Legionella bacterium was first identified in the summer of 1976 during the 58th annual convention of the American Legion, which was held at the Bellevue-Stratford Hotel in Philadelphia. Infection was presumed to be spread by contamination of the water in the hotel's air conditioning system. The presentation ranged from mild flulike symptoms to multisystem organ failure. Of the 182 people infected, 29 died. A bacterium that would later be named L pneumophila was isolated from different organ tissues of guinea pigs inoculated with lung tissue samples from 4 individuals who died. Although this pathogen was not identified until 1976, retrospective analysis suggests that L pneumophila may have been responsible for previous pneumonia epidemics in Philadelphia; Washington, DC; and Minnesota. L pneumophila was identified in a clinical specimen dating to 1943.
Legionellosis is the term that collectively describes infections caused by members of the Legionellaceae family. Legionnaires disease (LD) is the pneumonia caused by L pneumophila. LD also refers to a more benign, self-limited, acute febrile illness known as Pontiac fever, which has been linked serologically to L pneumophila, although it presents without pneumonia.
Pathophysiology
The Legionella bacterium is a small, aerobic, waterborne, gram-negative, unencapsulated bacillus that is nonmotile, catalase-positive, and weakly oxidase-positive. Legionella is a fastidious organism and does not grow anaerobically or on standard media. Buffered charcoal yeast extract (CYE) agar is the primary medium used for isolation of the bacterium.
The Legionellaceae family consists of more than 42 species constituting 64 serogroups. L pneumophila is the most common species, causing up to 90% of the cases of legionellosis, followed by Legionella micdadei (otherwise known as the Pittsburgh pneumonia agent), Legionella bozemanii, Legionella dumoffii, and Legionella longbeachae. Fifteen serogroups of L pneumophila have been identified, with serogroups 1, 4, and 6 being the primary causes of human disease. Serogroup 1 is thought to be responsible for 80% of the reported cases of legionellosis caused by L pneumophila.
Legionella species are obligate or facultative intracellular parasites. Water is the major environmental reservoir for Legionella. The bacterium can infect and replicate within protozoa such as Acanthamoeba and Hartmannella species, which are free-living amoebae found in both natural and manufactured water systems. The Legionella species within the amebic cells can avoid the endosomal-lysosomal pathway and can replicate within the phagosome. Legionella can survive and grow in the amebic cells, thereby enabling the organism to persist in nature.
Legionella species infect human macrophages and monocytes, and intracellular replication of the bacterium is observed within these cells in the alveoli. The intracellular infections of protozoa and macrophages have many similarities.
Transmission is thought to occur via inhalation of aerosolized mist from water sources (eg, whirlpools, showers, cooling towers1 ) contaminated with either the bacterium or amebic cells infected with the bacterium. Direct inhalation is the most likely method of transmission, with aerosol-generating systems playing a crucial role.2 Person-to-person transmission has not been documented. The highest incidence occurs during the warmer months, when air-conditioning systems are used more frequently. Nosocomial acquisition likely occurs via aspiration3 , respiratory therapy equipment2 , or contaminated water. In addition, transmission has been linked to the use of humidifiers, nebulizers, and items that were rinsed with contaminated tap water.
The following features increase the likelihood of colonization and amplification of legionellae in man-made water environments: (1) temperature of 25-42°C, (2) stagnation, (3) scale and sediment, and (4) presence of certain free-living aquatic amoebae capable of supporting intracellular growth of legionellae. Legionellae can resist low levels of chlorine used in water distribution systems.
Activated T cells produce lymphokines that stimulate increased antimicrobial activity of macrophages. This cell-mediated activation is key to halting the intracellular growth of legionellae. The significant role of cellular immunity explains why legionellae are observed more frequently in immunocompromised patients. Humoral immunity is thought to play a secondary role in the host response to legionellae infection.
Frequency
United States
LD has a reported incidence of 8000-18,000 cases per year. In certain geographic areas, community-acquired LD is more common.
LD is reportable in all 50 states. Only 5-10% of cases are estimated to be reported. While most cases of LD are sporadic, 10-20% are linked to outbreaks. LD is among the top 3-4 microbial causes of CAP, constituting approximately 1-9% of patients with CAP who require hospitalization. LD is an even more common cause of severe pneumonia in patients who require admission to an intensive care unit (ICU). LD ranks second, after pneumococcal pneumonia, as the etiology of pneumonia severe enough to require ICU admission.
Some LD cases are acquired in the hospital; they usually occur as outbreaks. Legionellae in the hospital setting is usually due to its presence in water sources and on surfaces (eg, pipes, rubber, plastics). The organism is also found in water sediment, which may explain its ability to persist despite flushing of hospital water systems.
International
LD is thought to occur worldwide and to be the cause of 2-15% of all CAP cases that require hospitalization.
Mortality/Morbidity
The mortality rate may approach 100% in patients with underlying disease. In untreated patients, the mortality rate may be as high as 80%.
Sex
Men have a greater risk of acquiring L pneumophila infection.
Age
Elderly persons have a greater risk of acquiring infection with Legionella species.
Clinical
History
L pneumophila causes 2 distinct disease entities. Legionnaires disease (LD) is characterized by pneumonia. Pontiac fever is a milder illness than LD and is not characterized by pneumonia; Pontiac fever manifests as fever and myalgias that resolve without treatment.
- Legionnaires disease
- The incubation period ranges from 2-10 days.
- Patients who develop legionellae infection and who have been hospitalized continuously for 10 or more days before the onset of illness are classified as having definite nosocomial LD. Patients with laboratory-confirmed infection that develops 2-9 days after hospitalization are classified as having possible nosocomial LD.
- Nosocomial LD occurs in clusters.
- Individuals with LD can present with a broad spectrum of symptoms.
- Symptoms of legionnaires disease
- Fever greater than 40 º C (>102 º F)
- Chills
- Cough - Dry or productive; hemoptysis rare
- Pleuritic or nonpleuritic chest pain
- Neurologic symptoms
- Headache
- Lethargy
- Encephalopathy
- Mental status changes - The most common neurologic symptom
- GI symptoms
- Diarrhea - Watery, not bloody
- Nausea, vomiting, and abdominal pain
- Myalgias
Physical
- Manifestations of LD may include the following:
- Mental status changes
- Fever greater than 40°C (range, 38.8-40.5°C)
- Hypotension
- Relative bradycardia in all (excluding patients with pacemakers or arrhythmias or those receiving beta-blockers, diltiazem, or verapamil)
- Tachypnea
- Localized rales
- Depressed mental status or agitation
- Extrapulmonary manifestations
- In addition to relative bradycardia, cardiac manifestations are common findings and include myocarditis, pericarditis, and prosthetic valve endocarditis.
- Pancreatitis
- Peritonitis
- Acute renal failure
Modified Winthrop-University Hospital Infection Disease Division's Point System for Diagnosing Legionnaires Disease in Adults
Open table in new window
Table
| Clinical Features | Qualifying Conditions | Point Score |
| Temperature >103°F* | With relative bradycardia | +5 |
| Headache | Acute onset | +2 |
| Mental confusion/lethargy* | Not drug induced | +4 |
| Ear pain | Acute onset | -3 |
| Nonexudative pharyngitis | Acute onset | -3 |
| Hoarseness | Acute, not chronic | -3 |
| Sputum (purulent) | Excluding chronic bronchitis | -3 |
| Hemoptysis* | Mild/moderate | -3 |
| Chest pain (pleuritic) | Rapidly progressive asymmetrical infiltrates* (excluding severe influenza/severe acute respiratory syndrome) | -3 |
| Loose stools/watery diarrhea* | Not drug induced | +3 |
| Abdominal pain* | With or without diarrhea | +5 |
| Renal failure* | Acute, not chronic | +3 |
| Shock/hypotension* | Not 2° to acute cardiac | -5 |
| /pulmonary causes | +5 | |
| Splenomegaly | Excluding non-CAP causes | -5 |
| Lack of response to beta lactams | After 72 h (excluding viral pneumonias) | +5 |
| Laboratory Features | ||
| Chest radiograph | Rapidly progressive asymmetrical infiltrates* (excluding severe influenza/SARS) | +3 |
| ↓ PO2 with ↑ A-a gradient (>35)* | (Excluding severe influenza/SARS) | -5 |
| ↓ Na+ | Acute onset | +1 |
| ↓ PO4 =* | Acute onset | +5 |
| ↑ SGOT/SGPT (early mild/transient)* | Acute onset | +4 |
| ↑ Total bilirubin | Otherwise unexplained | +1 |
| ↑ LDH (>400 U/L)* | Excluding HIV/PCP | -5 |
| ↑ CPK/aldolase | Otherwise unexplained | +4 |
| ↑ CRP (>30 mg/L) | Acute onset | +5 |
| ↑ Cold agglutinins (≥1:64) | Acute onset | -5 |
| ↑ Creatinine | Acute onset | +2 |
| Microscopic hematuria* | Excluding trauma, BPH, Foley catheter, bladder/renal neoplasms | +2 |
| Likelihood of Legionella infection | ||
| Total points | >15 Legionella infection very likely | |
| 5-15 Legionella infection likely | ||
| <5 Legionella infection unlikely | ||
| Clinical Features | Qualifying Conditions | Point Score |
| Temperature >103°F* | With relative bradycardia | +5 |
| Headache | Acute onset | +2 |
| Mental confusion/lethargy* | Not drug induced | +4 |
| Ear pain | Acute onset | -3 |
| Nonexudative pharyngitis | Acute onset | -3 |
| Hoarseness | Acute, not chronic | -3 |
| Sputum (purulent) | Excluding chronic bronchitis | -3 |
| Hemoptysis* | Mild/moderate | -3 |
| Chest pain (pleuritic) | Rapidly progressive asymmetrical infiltrates* (excluding severe influenza/severe acute respiratory syndrome) | -3 |
| Loose stools/watery diarrhea* | Not drug induced | +3 |
| Abdominal pain* | With or without diarrhea | +5 |
| Renal failure* | Acute, not chronic | +3 |
| Shock/hypotension* | Not 2° to acute cardiac | -5 |
| /pulmonary causes | +5 | |
| Splenomegaly | Excluding non-CAP causes | -5 |
| Lack of response to beta lactams | After 72 h (excluding viral pneumonias) | +5 |
| Laboratory Features | ||
| Chest radiograph | Rapidly progressive asymmetrical infiltrates* (excluding severe influenza/SARS) | +3 |
| ↓ PO2 with ↑ A-a gradient (>35)* | (Excluding severe influenza/SARS) | -5 |
| ↓ Na+ | Acute onset | +1 |
| ↓ PO4 =* | Acute onset | +5 |
| ↑ SGOT/SGPT (early mild/transient)* | Acute onset | +4 |
| ↑ Total bilirubin | Otherwise unexplained | +1 |
| ↑ LDH (>400 U/L)* | Excluding HIV/PCP | -5 |
| ↑ CPK/aldolase | Otherwise unexplained | +4 |
| ↑ CRP (>30 mg/L) | Acute onset | +5 |
| ↑ Cold agglutinins (≥1:64) | Acute onset | -5 |
| ↑ Creatinine | Acute onset | +2 |
| Microscopic hematuria* | Excluding trauma, BPH, Foley catheter, bladder/renal neoplasms | +2 |
| Likelihood of Legionella infection | ||
| Total points | >15 Legionella infection very likely | |
| 5-15 Legionella infection likely | ||
| <5 Legionella infection unlikely | ||
*Otherwise unexplained (acute and associated with pneumonia)
Adapted from Cunha BA. Antibiotic Essentials. 5th ed. Royal Oak, Mich: Physicians Press; 2006.
- A clinical point score may be helpful in increasing probability of LD and prompting specific/definitive LD testing.
Causes
The risk of infection increases with the type and intensity of the exposure, as well as the health status of the exposed individual. Numerous factors increase the risk of acquiring legionellae infections.
- Risk factors for infection
- Advanced age
- Smoking
- Chronic heart or lung disease
- Immunocompromised state or immunosuppressive medication use (especially corticosteroids)
- Recent exposure to water or soil
- Pediatric cases of Legionella pneumonia are less common. Most of these cases occur in children who are immunosuppressed or in immunocompetent children who have undergone surgery or who are on a ventilator.
More on Legionnaires Disease |
Overview: Legionnaires Disease |
| Differential Diagnoses & Workup: Legionnaires Disease |
| Treatment & Medication: Legionnaires Disease |
| Follow-up: Legionnaires Disease |
| References |
| Next Page » |
References
Nguyen TM, Ilef D, Jarraud S, Rouil L, Campese C, Che D. A community-wide outbreak of legionnaires disease linked to industrial cooling towers--how far can contaminated aerosols spread?. J Infect Dis. Jan 1 2006;193(1):102-11. [Medline].
Woo AH, Goetz A, Yu VL. Transmission of Legionella by respiratory equipment and aerosol generating devices. Chest. Nov 1992;102(5):1586-90. [Medline].
Yu VL. Could aspiration be the major mode of transmission for Legionella?. Am J Med. Jul 1993;95(1):13-5. [Medline].
Cunha BA. Hypophosphatemia: diagnostic significance in Legionnaires' disease. Am J Med. Jul 2006;119(7):e5-6. [Medline].
Kashuba AD, Ballow CH. Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Diagn Microbiol Infect Dis. Mar 1996;24(3):129-39. [Medline].
Helbig JH, Engelstadter T, Maiwald M, et al. Diagnostic relevance of the detection of Legionella DNA in urine samples by the polymerase chain reaction. Eur J Clin Microbiol Infect Dis. Oct 1999;18(10):716-22. [Medline].
Tan MJ, Tan JS, Hamor RH, File TM Jr, Breiman RF. The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest. Feb 2000;117(2):398-403. [Medline].
Tano E, Cars O, Löwdin E. Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. J Antimicrob Chemother. Jul 2005;56(1):240-2. [Medline].
Amsden GW. Treatment of Legionnaires' disease. Drugs. 2005;65(5):605-14. [Medline].
Baltch AL, Bopp LH, Smith RP, Michelsen PB, Ritz WJ. Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. J Antimicrob Chemother. Jul 2005;56(1):104-9. [Medline].
Blázquez Garrido RM, Espinosa Parra FJ, Alemany Francés L, Ramos Guevara RM, Sánchez-Nieto JM, Segovia Hernández M. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis. Mar 15 2005;40(6):800-6. [Medline].
Cunha BA. Antibiotic Essentials. 6th ed. Royal Oak, Mich: Physicians Press; 2007.
Cunha BA. Antimicrobial Therapy of Legionnaire's Disease. In: Rakel RE, ed. Conn's Current Therapy. 53rd ed. Philadelphia, Pa: WB Saunders; 2001.
Cunha BA. Pneumonia Essentials. Royal Oak, Mich: Physicians Press; 2007.
Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect. May 2006;12 Suppl 3:12-24. [Medline].
Cunha BA. Legionella pneumonia: The value of clinical and laboratory findings. J Respir Dis. 2005;26:459-60.
Den Boer JW, Yzerman EP. Diagnosis of Legionella infection in Legionnaires' disease. Eur J Clin Microbiol Infect Dis. Dec 2004;23(12):871-8. [Medline].
Edelstein PH. Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann Intern Med. Aug 15 1998;129(4):328-30. [Medline].
Edelstein PH. Antimicrobial chemotherapy for legionnaires' disease: a review. Clin Infect Dis. Dec 1995;21 Suppl 3:S265-76. [Medline].
Fraser DW, Tsai TR, Orenstein W, Parkin WE, Beecham HJ, Sharrar RG. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med. Dec 1 1977;297(22):1189-97. [Medline].
Hart CA, Makin T. Legionella in hospitals: a review. J Hosp Infect. Jun 1991;18 Suppl A:481-9. [Medline].
Johnson DH, Cunha BA. Atypical pneumonias. Clinical and extrapulmonary features of Chlamydia, Mycoplasma, and Legionella infections. Postgrad Med. May 15 1993;93(7):69-72, 75-6, 79-82. [Medline].
Klein NC, Cunha BA. Treatment of legionnaires' disease. Semin Respir Infect. Jun 1998;13(2):140-6. [Medline].
Kura F, Amemura-Maekawa J, Yagita K, Endo T, Ikeno M, Tsuji H. Outbreak of Legionnaires' disease on a cruise ship linked to spa-bath filter stones contaminated with Legionella pneumophila serogroup 5. Epidemiol Infect. Apr 2006;134(2):385-91. [Medline].
Li Gobbi F, Benucci M, Del Rosso A. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab). J Clin Rheumatol. Apr 2005;11(2):119-20. [Medline].
Lieberman D, Porath A, Schlaeffer F, et al. Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients. Chest. May 1996;109(5):1243-9. [Medline].
Lin YS, Yu VL. Underdiagnosis of hospital-acquired Legionnaires disease in Singapore. Am J Infect Control. Apr 2006;34(3):161-2. [Medline].
McDade JE, Shepard CC, Fraser DW, Tsai TR, Redus MA, Dowdle WR. Legionnaires' disease: isolation of a bacterium and demonstration of its role in other respiratory disease. N Engl J Med. Dec 1 1977;297(22):1197-203. [Medline].
Ongut G, Yavuz A, Ogunc D, Tuncer M, Ozturk F, Mutlu D. Seroprevalence of antibodies to legionella pneumophila in hemodialysis patients. Transplant Proc. Jan-Feb 2004;36(1):44-6. [Medline].
Pedro-Botet L, Yu VL. Legionella: macrolides or quinolones?. Clin Microbiol Infect. May 2006;12 Suppl 3:25-30. [Medline].
Plouffe JF, File TM Jr, Breiman RF, Hackman BA, Salstrom SJ, Marston BJ. Reevaluation of the definition of Legionnaires' disease: use of the urinary antigen assay. Community Based Pneumonia Incidence Study Group. Clin Infect Dis. May 1995;20(5):1286-91. [Medline].
Ricketts KD, Joseph CA. The distribution of travel-associated Legionnaires' disease within selected European countries, and a comparison with tourist patterns. Epidemiol Infect. Aug 2006;134(4):887-93. [Medline].
Ricketts KD, McNaught B, Joseph CA. Travel-associated legionnaires' disease in Europe: 2004. Euro Surveill. 2006;11(4):107-10. [Medline].
Roig J, Domingo C, Morera J. Legionnaires' disease. Chest. Jun 1994;105(6):1817-25. [Medline].
Sabrià M, Pedro-Botet ML, Gómez J, Roig J, Vilaseca B, Sopena N. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest. Sep 2005;128(3):1401-5. [Medline].
Seenivasan MH, Yu VL, Muder RR. Legionnaires' disease in long-term care facilities: overview and proposed solutions. J Am Geriatr Soc. May 2005;53(5):875-80. [Medline].
Stout JE, Yu VL. Legionellosis. N Engl J Med. Sep 4 1997;337(10):682-7. [Medline].
Winiecka-Krusnell J, Linder E. Free-living amoebae protecting Legionella in water: the tip of an iceberg?. Scand J Infect Dis. 1999;31(4):383-5. [Medline].
Yu VL, Kroboth FJ, Shonnard J, Brown A, McDearman S, Magnussen M. Legionnaires' disease: new clinical perspective from a prospective pneumonia study. Am J Med. Sep 1982;73(3):357-61. [Medline].
[Guideline] Yu VL, Ramirez J, Roig J, Sabria M. Legionnaires disease and the updated IDSA guidelines for community-acquired pneumonia. Clin Infect Dis. Dec 1 2004;39(11):1734-7; author reply 1737-8. [Medline].
Further Reading
Keywords
legionnaire disease, LD, Legionella pneumonia, Legionella pneumophila, L pneumophila, legionellosis, legionnaires disease, Pontiac fever, nosocomial pneumonia, community-acquired pneumonia, Legionella micdadei, L micdadei, Legionella bozemanii, L bozemanii, Legionella dumoffii, L dumoffii, Legionella longbeachae, L longbeachae, Pittsburgh pneumonia agent
Overview: Legionnaires Disease